Applied Health Economics and Health Policy

, Volume 10, Issue 3, pp 145–162 | Cite as

Economic evaluations of adult weight management interventions

A systematic literature review focusing on methods used for determining health impacts
  • Ulla K. Griffiths
  • Benedict Anigbogu
  • Kiran Nanchahal
Systematic Review

Abstract

Background

One of the challenges when undertaking economic evaluations of weight management interventions is to adequately assess future health impacts. Clinical trials commonly measure impacts using surrogate outcomes, such as reductions in body mass index, and investigators need to decide how these can best be used to predict future health effects. Since obesity is associated with an increased risk of numerous chronic diseases occurring at different future time points, modelling is needed for predictions.

Objective

To assess the methods used in economic evaluations to determine health impacts of weight management interventions and to investigate whether differences in methods affect the cost-effectiveness estimates.

Methods

Eight databases were systematically searched. Included studies were categorized according to a decision analytic approach and effect measures incorporated.

Results

A total of 44 articles were included; 21 evaluated behavioural interventions, 12 evaluated surgical procedures and 11 evaluated pharmacological compounds. Of the 27 papers that estimated future impacts, eleven used Markov modelling, seven used a decision tree, five used a mathematical application, two used patient-level simulation and the modelling method was unclear in two papers. The most common types of effects included were co-morbidity treatment costs, heath-related quality of life due to weight loss and gain in survival. Only 12 of the studies included heath-related quality of life gains due to reduced co-morbidities and only one study included productivity gains. Despite consensus that trial-based analysis on its own is inadequate in guiding resource allocation decisions, it was used in 39% of the studies. Several of the modelling papers used model structures not suitable for chronic diseases with changing health risks.

Three studies concluded that the intervention dominated standard care; meaning that it generated more quality-adjusted life-years (QALYs) for less cost. The incremental costs per QALY gained varied from $US235 to $US56 836 in the remaining studies using this outcome measure. An implicit hypothesis of the review was that studies including long-term health effects would illustrate greater cost effectiveness compared with trial-based studies. This hypothesis is partly confirmed with three studies arriving at dominating results, as these reach their conclusion from modelling future co-morbidity treatment cost savings. However, for the remaining studies there is little indication that decision-analytic modelling disparities explain the differences.

Conclusions

This is the first literature review comparing methods used in economic evaluations of weight management interventions, and it is the first time that observed differences in study results are addressed with a view to methodological explanations. We conclude that many studies have methodological deficiencies and we urge analysts to follow recommended practices and use models capable of depicting long-term health consequences.

Notes

Acknowledgements

The study was funded by Camden Primary Health Care Trust, UK. The authors have no conflicts of interest that are directly relevant to the content of this article.

UKG conceived the idea, abstracted data, undertook the analysis and wrote the paper. BA conducted the literature search, abstracted data and commented on the paper. KN assisted with analysis and commented on the paper. UKG acts as guarantor for the overall content.

References

  1. 1.
    Cecchini M, Sassi F, Lauer JA, et al. Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness. Lancet 2010 Nov 20; 376(9754): 1775–84PubMedCrossRefGoogle Scholar
  2. 2.
    Dixon JB. The effect of obesity on health outcomes. Mol Cell Endocrinol 2010 Mar 25; 316(2): 104–8PubMedCrossRefGoogle Scholar
  3. 3.
    National Institute of Clinical Excellence. Guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children. London: NICE; 2006 DecGoogle Scholar
  4. 4.
    Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005Google Scholar
  5. 5.
    Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997 May-Jun; 6(3): 217–27PubMedCrossRefGoogle Scholar
  6. 6.
    Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. Pharmacoeconomics 2000 May; 17(5): 461–77PubMedCrossRefGoogle Scholar
  7. 7.
    Sculpher MJ, Claxton K, Drummond M, et al. Whither trial-based economic evaluation for health care decision making? Health Econ 2006 Jul; 15(7): 677–87PubMedCrossRefGoogle Scholar
  8. 8.
    Avenell A, Broom J, Brown TJ, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004 May; 8(21): iii–182PubMedGoogle Scholar
  9. 9.
    Clegg AJ, Colquitt J, Sidhu MK, et al. The clinical effectiveness and cost-effectiveness of surgery for people with morbid obesity: a systematic review and economic evaluation. Health Technol Assess 2002; 6(12): 1–153PubMedGoogle Scholar
  10. 10.
    Picot J, Jones J, Colquitt JL, et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess 2009 Sep; 13(41): ix–214Google Scholar
  11. 11.
    O’Meara S, Riemsma R, Shirran L, et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technol Assess 2001; 5(18): 1–81Google Scholar
  12. 12.
    Neovius M, Narbro K. Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review. Int J Obes 2008 Dec; 32(12): 1752–63CrossRefGoogle Scholar
  13. 13.
    Clegg A, Colquitt J, Sidhu M, et al. Clinical and cost effectiveness of surgery for morbid obesity: a systematic review and economic evaluation. Int J Obes 2003 Oct; 27(10): 1167–77CrossRefGoogle Scholar
  14. 14.
    Briggs A, Schulper M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006Google Scholar
  15. 15.
    Briggs A, Sculpher M. Commentary: Markov models of medical prognosis. BMJ 1997 Feb 1; 314(7077): 354–5PubMedCrossRefGoogle Scholar
  16. 16.
    Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004 Sep; 8(36): iii-iv, ix-xi, 1-158Google Scholar
  17. 17.
    Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices — Modeling Studies. Value Health 2003 Jan-Feb; 6(1): 9–17PubMedCrossRefGoogle Scholar
  18. 18.
    International Monetary Fund. Data and statistics [online]. Available from URL: http://www.imf.org/external/data.htm [Accessed 2012 Mar 1]
  19. 19.
    Erfurt JC, Foote A, Heirich MA. The cost-effectiveness of worksite wellness programs for hypertension control, weight loss, smoking cessation, and exercise. Personnel Psychol 1992; 45(1): 5–27CrossRefGoogle Scholar
  20. 20.
    Galani C, Al M, Schneider H, et al. Uncertainty in decision-making: value of additional information in the cost-effectiveness of lifestyle intervention in overweight and obese people. Value Health 2008 May; 11(3): 424–34PubMedCrossRefGoogle Scholar
  21. 21.
    Jacobs-van der Bruggen MA, Bos G, Bemelmans WJ, et al. Lifestyle interventions are cost-effective in people with different levels of diabetes risk: results from a modeling study. Diabetes Care 2007 Jan; 30(1): 128–34CrossRefGoogle Scholar
  22. 22.
    Anselmino M, Bammer T, Fernandez Cebrian JM, et al. Cost-effectiveness and budget impact of obesity surgery in patients with type 2 diabetes in three European countries(II). Obes Surg 2009 Nov; 19(11): 1542–9PubMedCrossRefGoogle Scholar
  23. 23.
    Brennan A, Ara R, Sterz R, et al. Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany. Eur J Health Econ 2006 Dec; 7(4): 276–84PubMedCrossRefGoogle Scholar
  24. 24.
    Barton GR, Sach TH, Jenkinson C, et al. Lifestyle interventions for knee pain in overweight and obese adults aged > or=45: economic evaluation of randomised controlled trial. BMJ 2009; 339: b2273PubMedCrossRefGoogle Scholar
  25. 25.
    Salkeld G, Phongsavan P, Oldenburg B, et al. The cost-effectiveness of a cardiovascular risk reduction program in general practice. Health Pol 1997 Aug; 41(2): 105–19CrossRefGoogle Scholar
  26. 26.
    Clarke P, Gray A, Adler A, et al. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia 2001; 44(3): 298–304PubMedCrossRefGoogle Scholar
  27. 27.
    Agras W, Taylor C, Feldman DE, et al. Developing computer-assisted therapy for the treatment of obesity. Behav Ther 1990 Win; 21(1): 99–109CrossRefGoogle Scholar
  28. 28.
    Meyers AW, Graves TJ, Whelan JP, et al. An evaluation of a television-delivered behavioral weight loss program: are the ratings acceptable? J Consult Clin Psychol 1996; 64(1): 172–8PubMedCrossRefGoogle Scholar
  29. 29.
    Harvey-Berino J. Changing health behavior via telecommunications technology: using interactive television to treat obesity. Behav Ther 1998 Jun; 29(3): 505–19CrossRefGoogle Scholar
  30. 30.
    Pritchard DA, Hyndman J, Taba F. Nutritional counselling in general practice: a cost effective analysis. J Epidemiol Commun Health 1999 May; 53(5): 311–6CrossRefGoogle Scholar
  31. 31.
    Wylie-Rosett J, Swencionis C, Ginsberg M, et al. Computerized weight loss intervention optimizes staff time: the clinical and cost results of a controlled clinical trial conducted in a managed care setting. J Am Dietetic Assoc 2001; 101(10): 1155–62CrossRefGoogle Scholar
  32. 32.
    Dzator JA, Hendrie D, Burke V, et al. A randomized trial of interactive group sessions achieved greater improvements in nutrition and physical activity at a tiny increase in cost. J Clin Epidemiol 2004; 57(6): 610–9PubMedCrossRefGoogle Scholar
  33. 33.
    Olsen J, Willaing I, Ladelund S, et al. Cost-effectiveness of nutritional counseling for obese patients and patients at risk of ischemic heart disease. Int J Technol Assess Health Care 2005 Spring; 21(2): 194–202PubMedGoogle Scholar
  34. 34.
    Tsai AG, Glick HA, Shera D, et al. Cost-effectiveness of a low-carbohydrate diet and a standard diet in severe obesity. Obes Res 2005 Oct; 13(10): 1834–40PubMedCrossRefGoogle Scholar
  35. 35.
    Roux L, Kuntz KM, Donaldson C, et al. Economic evaluation of weight loss interventions in overweight and obese women. Obesity 2006 Jun; 14(6): 1093–106PubMedCrossRefGoogle Scholar
  36. 36.
    Galani C, Schneider H, Rutten FF. Modelling the lifetime costs and health effects of lifestyle intervention in the prevention and treatment of obesity in Switzerland. Int J Public Health 2007; 52(6): 372–82PubMedCrossRefGoogle Scholar
  37. 37.
    McConnon A, Kirk SF, Cockroft JE, et al. The Internet for weight control in an obese sample: results of a randomised controlled trial. BMC Health Serv Res 2007; 7: 206PubMedCrossRefGoogle Scholar
  38. 38.
    Bemelmans W, van Baal P, Wendel-Vos W, et al. The costs, effects and cost-effectiveness of counteracting overweight on a population level: a scientific base for policy targets for the Dutch national plan for action. Prev Med 2008; 46(2): 127–32PubMedCrossRefGoogle Scholar
  39. 39.
    Gusi N, Reyes MC, Gonzalez-Guerrero JL, et al. Cost-utility of a walking programme for moderately depressed, obese, or overweight elderly women in primary care: a randomised controlled trial. BMC Public Health 2008; 8: 231PubMedCrossRefGoogle Scholar
  40. 40.
    Gustafson A, Khavjou O, Stearns SC, et al. Cost-effectiveness of a behavioral weight loss intervention for low-income women: the Weight-Wise Program. Prev Med 2009; 49(5): 390–5PubMedCrossRefGoogle Scholar
  41. 41.
    Sevick MA, Miller GD, Loeser RF, et al. Cost-effectiveness of exercise and diet in overweight and obese adults with knee osteoarthritis. Med Sci Sports Exerc 2009; 41(6): 1167–74PubMedCrossRefGoogle Scholar
  42. 42.
    Befort CA, Donnelly JE, Sullivan DK, et al. Group versus individual phone-based obesity treatment for rural women. Eat Behav 2010; 11(1): 11–7PubMedCrossRefGoogle Scholar
  43. 43.
    Cobiac L, Vos T, Veerman L. Cost-effectiveness of Weight Watchers and the Lighten Up to a Healthy Lifestyle program. Aust N Z J Public Health 2010 Jun; 34(3): 240–7PubMedCrossRefGoogle Scholar
  44. 44.
    Joo NS, Park YW, Park KH, et al. Cost-effectiveness of a community-based obesity control programme. J Telemed Telecare 2010; 16(2): 63–7PubMedCrossRefGoogle Scholar
  45. 45.
    Rasu RS, Hunter CM, Peterson AL, et al. Economic evaluation of an Internet-based weight management program. Am J Manage Care 2010; 16(4): 98–104Google Scholar
  46. 46.
    Trueman P, Haynes SM, Felicity Lyons G, et al. Long-term cost-effectiveness of weight management in primary care. Int J Clin Pract 2010; 64(6): 775–83PubMedCrossRefGoogle Scholar
  47. 47.
    van Gemert WG, Adang EM, Kop M, et al. A prospective cost-effectiveness analysis of vertical banded gastroplasty for the treatment of morbid obesity. Obes Surg 1999 Oct; 9(5): 484–91PubMedCrossRefGoogle Scholar
  48. 48.
    Craig BM, Tseng DS. Cost-effectiveness of gastric bypass for severe obesity. Am J Med 2002; 113(6): 491–8PubMedCrossRefGoogle Scholar
  49. 49.
    Jensen C, Flum DR. The costs of nonsurgical and surgical weight loss interventions: is an ounce of prevention really worth a pound of cure? Surg Obes Relat Dis 2005 May-Jun; 1(3): 353–7PubMedCrossRefGoogle Scholar
  50. 50.
    Ackroyd R, Mouiel J, Chevallier JM, et al. Cost-effectiveness and budget impact of obesity surgery in patients with type-2 diabetes in three European countries. Obes Surg 2006 Nov; 16(11): 1488–503PubMedCrossRefGoogle Scholar
  51. 51.
    van Mastrigt GA, van Dielen FM, Severens JL, et al. One-year cost-effectiveness of surgical treatment of morbid obesity: vertical banded gastroplasty versus Lap-Band. Obes Surg 2006 Jan; 16(1): 75–84PubMedCrossRefGoogle Scholar
  52. 52.
    Salem L, Devlin A, Sullivan SD, et al. Cost-effectiveness analysis of laparoscopic gastric bypass, adjustable gastric banding, and nonoperative weight loss interventions. Surg Obes Relat Dis 2008 Jan; 4(1): 26–32PubMedCrossRefGoogle Scholar
  53. 53.
    Ikramuddin S, Klingman D, Swan T, et al. Cost-effectiveness of Roux-en-Y gastric bypass in type 2 diabetes patients. Am J Manag Care 2009 Sep; 15(9): 607–15PubMedGoogle Scholar
  54. 54.
    Keating CL, Bulfone L, Dixon JB, et al. Cost-effectiveness of surgically induced weight loss for the management of type 2 diabetes: modeled lifetime analysis. Diabetes Care 2009 April; 32(4): 567–74PubMedCrossRefGoogle Scholar
  55. 55.
    Campbell J, McGarry LA, Shikora SA, et al. Cost-effectiveness of laparoscopic gastric banding and bypass for morbid obesity. Am J Manag Care 2010 Jul; 16(7): 174–87Google Scholar
  56. 56.
    McEwen LN, Coelho RB, Baumann LM, et al. The cost, quality of life impact, and cost-utility of bariatric surgery in a managed care population. Obes Surg 2010 Jul; 20(7): 919–28PubMedCrossRefGoogle Scholar
  57. 57.
    Hoerger TJ, Zhang P, Segel JE, et al. Cost-effectiveness of bariatric surgery for severely obese adults with diabetes. Diabetes Care 2010 Sep; 33(9): 1933–9PubMedCrossRefGoogle Scholar
  58. 58.
    Lamotte M, Annemans L, Lefever A, et al. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care 2002 Feb; 25(2): 303–8PubMedCrossRefGoogle Scholar
  59. 59.
    Maetzel A, Ruof J, Covington M, et al. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus. Pharmacoeconomics 2003; 21(7): 501–12PubMedCrossRefGoogle Scholar
  60. 60.
    Warren E, Brennan A, Akehurst R. Cost-effectiveness of sibutramine in the treatment of obesity. Med Decis Making 2004 Jan-Feb; 24(1): 9–19PubMedCrossRefGoogle Scholar
  61. 61.
    Foxcroft DR. Orlistat for the treatment of obesity: cost utility model. Obes Rev 2005 Nov; 6(4): 323–8PubMedCrossRefGoogle Scholar
  62. 62.
    Hertzman P. The cost-effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden: a treatment responder approach. Pharmacoeconomics 2005; 23(10): 1007–20PubMedCrossRefGoogle Scholar
  63. 63.
    Lacey LA, Wolf A, O’shea D, et al. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland. Int J Obes 2005 Aug; 29(8): 975–82CrossRefGoogle Scholar
  64. 64.
    Malone DC, Raebel MA, Porter JA, et al. Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program. J Manage Care Pharm; 2005; 458–68Google Scholar
  65. 65.
    Caro JJ, Stillman IO, Danel A, et al. Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model. J Med Econ 2007; 10(3): 239–54CrossRefGoogle Scholar
  66. 66.
    Hampp C, Hartzema AG, Kauf TL. Cost-utility analysis of rimonabant in the treatment of obesity. Value Health 2008 May-Jun; 11(3): 389–99PubMedCrossRefGoogle Scholar
  67. 67.
    Iannazzo S, Zaniolo O, Pradelli L. Economic evaluation of treatment with orlistat in Italian obese patients. Curr Med Res Opin 2008 Jan; 24(1): 63–74PubMedGoogle Scholar
  68. 68.
    van Baal PH, van den Berg M, Hoogenveen RT, et al. Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling long-term health gains through prevention of obesity-related chronic diseases. Value Health 2008 Dec; 11(7): 1033–40PubMedCrossRefGoogle Scholar
  69. 69.
    Flegal KM, Graubard BI, Williamson DF, et al. Excess deaths associated with underweight, overweight, and obesity. JAMA 2005 Apr 20; 293(15): 1861–7PubMedCrossRefGoogle Scholar
  70. 70.
    Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Eng J Med 2007; 357(8): 741–52CrossRefGoogle Scholar
  71. 71.
    van Gemert WG, Adang EM, Kop M, et al. A prospective cost-effectiveness analysis of vertical banded gastroplasty for the treatment of morbid obesity. Obes Surg 1999 Oct; 9(5): 484–91PubMedCrossRefGoogle Scholar
  72. 72.
    Fontaine KR, Redden DT, Wang C, et al. Years of life lost due to obesity. JAMA 2003 Jan 8; 289 (2): 187–93Google Scholar
  73. 73.
    Anderson KM, Wilson PW, Odell PM, et al. An updated coronary risk profile: a statement for health professionals. Circulation 1991 Jan; 83(1): 356–62PubMedCrossRefGoogle Scholar
  74. 74.
    Thompson D, Edelsberg J, Colditz GA, et al. Lifetime health and economic consequences of obesity. Arch Intern Med 1999 Oct 11; 159(18): 2177–83PubMedCrossRefGoogle Scholar
  75. 75.
    Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001; 161(13): 1581–6PubMedCrossRefGoogle Scholar
  76. 76.
    Rexrode KM, Carey VJ, Hennekens CH, et al. Abdominal adiposity and coronary heart disease in women. JAMA 1998 Dec 2; 280(21): 1843–8PubMedCrossRefGoogle Scholar
  77. 77.
    Colditz GA, Willett WC, Rotnitzky A, et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122(7): 481–6PubMedGoogle Scholar
  78. 78.
    Sjostrom CD, Lissner L, Wedel H, et al. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999; 7(5): 477–84PubMedCrossRefGoogle Scholar
  79. 79.
    Magliano DJ, Shaw JE, Shortreed SM, et al. Lifetime risk and projected population prevalence of diabetes. Diabeto-logia 2008 Dec; 51(12): 2179–86CrossRefGoogle Scholar
  80. 80.
    Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 Aug 12; 321(7258): 405–12PubMedCrossRefGoogle Scholar
  81. 81.
    Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004 Aug; 20 Suppl. 1: S5–26CrossRefGoogle Scholar
  82. 82.
    Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004 Aug; 20 Suppl. 1: S27–40CrossRefGoogle Scholar
  83. 83.
    Hoerger TJ, Segel JE, Zhang P, et al. Validation of the CDC-RTI Diabetes Cost-Effectiveness Model. Research Triangle Park: RTI International, 2009CrossRefGoogle Scholar
  84. 84.
    Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009 Mar; 122(3): 248–56 e5PubMedCrossRefGoogle Scholar
  85. 85.
    Gregg EW, Cadwell BL, Cheng YJ, et al. Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the U.S. Diabetes Care 2004; 27(12): 2806–12PubMedCrossRefGoogle Scholar
  86. 86.
    Erfurt JC, Foote A, Heirich MA. The cost-effectiveness of work-site wellness programs for hypertension control, weight loss, and smoking cessation. J Occup Med 1991; 33(9): 962–70PubMedGoogle Scholar
  87. 87.
    Craig JC, McEwan P, Peters JR, et al. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health 2005; 8(5): 581–90CrossRefGoogle Scholar
  88. 88.
    Cohen J, Stolk E, Niezen M. The increasingly complex fourth hurdle for pharmaceuticals. Pharmacoeconomics 2007; 25(9): 727–34PubMedCrossRefGoogle Scholar
  89. 89.
    NICE. Guide to the methods of technology appraisal, 2008 June [online]. Available from URL: http://www.nice.org.uk/aboutnice/howwework/devnicetech/guidetothemethodsoftechnologyappraisal.jsp [Accessed 2012 Mar 1]
  90. 90.
    Bilcke J, Beutels P, Brisson M, et al. Accounting for methodological, structural, and parameter uncertainty in decision-analytic models: a practical guide. Med Decis Making 2011 Jul-Aug; 31(4): 675–92PubMedCrossRefGoogle Scholar
  91. 91.
    Sheldon TA. Problems of using modelling in the economic evaluation of health care. Health Econ 1996 Jan-Feb; 5(1): 1–11PubMedCrossRefGoogle Scholar
  92. 92.
    Kim LG, Thompson SG. Uncertainty and validation of health economic decision models. Health Econ 2010 Jan; 19(1): 43–55PubMedGoogle Scholar
  93. 93.
    Tarride JE, Hopkins R, Blackhouse G, et al. A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment. Pharmacoeconomics 2010; 28(4): 255–77PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Ulla K. Griffiths
    • 1
  • Benedict Anigbogu
    • 2
  • Kiran Nanchahal
    • 3
  1. 1.Department of Global Health and DevelopmentLondon School of Hygiene and Tropical MedicineLondonUK
  2. 2.National Collaboration Centre for Mental HealthRoyal College of PsychiatristsLondonUK
  3. 3.Department of Social and Environmental Health ResearchLondon School of Hygiene and Tropical MedicineLondonUK

Personalised recommendations